Mission Bio has launched the Tapestri Single-cell Multi-omics Solution – a comprehensive single-cell multi-omics platform. With a new instrument, single-cell multi-omics reagent kits, TotalSeq-D antibody content from BioLegend, and visualisation software, the package provides layered insight into multiple analytes across all blood cancers, reducing drug development time and cost by at least half. The company has parterned with BioLegend, provider of antibodies and reagents, to develop antibody panels for single-cell protein detection with the new device.
The complexity of cancer targeted therapies and what drives treatment response and resistance cannot be overcome without comprehensive tools. Running a large-scale clinical study costs around $40 million, and the pharmaceutical industry is losing $50 billion a year on failed clinical trials and ineffective drugs. It is essential to identify precision biomarkers and characterise resistance mechanisms – both DNA mutations and protein expression – to minimise losses, maximise treatment efficacy, and accelerate time to market.
“With our technology, you can unlock the ground truth of cancer: our DNA-Protein kit offers, for the first time, the ability to understand the communication pathway all the way from the blueprint of life in the centre of the cell – DNA – to the exterior of the cell via surface proteins, without inference or conjecture,” explained Nigel Beard, Chief Technology Officer and SVP of Operations of Mission Bio. “It’s a product builders’ dream, to deliver a disruptive technology that truly empowers our customers with the potential to unravel the many connected threads that make up the complexity of cancer.”
The value of connecting the mutations in single-cells with their immunophenotypes directly has been a game-changer in allowing us to discover cell surface markers that identify disease stem cells. Merging multiple assays saves us a tremendous amount of time and allows for better insights into disease biology so we can develop more precise and effective therapies,” said Stephen Chung, University of Texas, Southwestern Medical Center, where this technolgy has been adopted.
Image credit: National Cancer Institute
